Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation

M Ighilahriz; M Benfodda; H Sharpe; N Soufir; S Mourah; N Dumaz; M Battistella; A Savina; F Bouquet; S Nikolaev; N Basset-Seguin

doi:10.1111/jdv.15741

Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation

J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e422-e424. doi: 10.1111/jdv.15741. Epub 2019 Jul 15.

Authors

M Ighilahriz¹, M Benfodda^{1

2}, H Sharpe³, N Soufir^{1

2

4}, S Mourah^{1

4

5}, N Dumaz^{1

4}, M Battistella⁶, A Savina⁷, F Bouquet⁷, S Nikolaev^{1

4}, N Basset-Seguin^{1

4

6}

Affiliations

¹ Institute of Skin Research, INSERM U 976, Saint Louis Hospital, Paris, France.
² Département de Génétique, AP-HP, Hôpital Bichat Claude Bernard, Paris, France.
³ Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
⁴ Sorbonne Paris Cité, Université Paris-Diderot, Paris, France.
⁵ Pharmacology-Biologic Laboratory, AP-HP, Saint Louis University Hospital, Paris, France.
⁶ Department of Dermatology, AP-HP, Hôpital Saint-Louis, Paris, France.
⁷ Institut Roche, Boulogne-Billancourt, France.

PMID: 31187903
DOI: 10.1111/jdv.15741

No abstract available

Publication types

Letter

MeSH terms

Anilides / therapeutic use*
Carcinoma, Basal Cell / drug therapy*
Carcinoma, Basal Cell / genetics
Carcinoma, Basal Cell / pathology
Drug Resistance, Neoplasm / genetics*
Humans
Mutation*
Neoplasm Recurrence, Local*
Pyridines / therapeutic use*
Skin Neoplasms / drug therapy*
Skin Neoplasms / genetics
Skin Neoplasms / pathology

Substances

Anilides
HhAntag691
Pyridines

Grants and funding

F. Hoffmann-La Roche